Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Consolidated Net Income: 2012-2025

Historic Consolidated Net Income for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Consolidated Net Income fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Consolidated Net Income stood at -$103.4 million for Q3 2025, which was up 8.09% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Consolidated Net Income's 5-year high stood at $2.0 billion during Q1 2021, with a 5-year trough of -$112.5 million in Q2 2025.
  • In the last 3 years, Agios Pharmaceuticals' Consolidated Net Income had a median value of -$91.3 million in 2023 and averaged $796,545.
  • In the last 5 years, Agios Pharmaceuticals' Consolidated Net Income spiked by 4,382.87% in 2021 and then crashed by 2,696.82% in 2022.
  • Agios Pharmaceuticals' Consolidated Net Income (Quarterly) stood at $4.0 million in 2021, then crashed by 2,442.28% to -$92.7 million in 2022, then dropped by 3.51% to -$95.9 million in 2023, then dropped by 0.61% to -$96.5 million in 2024, then slumped by 110.91% to -$103.4 million in 2025.
  • Its last three reported values are -$103.4 million in Q3 2025, -$112.5 million for Q2 2025, and -$90.5 million during Q1 2025.